Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition
CDXC Stock | USD 7.59 0.13 1.74% |
About 61% of all Chromadex Corp's shareholders are looking to take a long position. The analysis of overall sentiment of trading Chromadex Corp stock suggests that some investors are interested at this time. The current market sentiment, together with Chromadex Corp's historical and current headlines, can help investors time the market. In addition, many technical investors use Chromadex Corp stock news signals to limit their universe of possible portfolio assets.
Chromadex |
ChromaDex Corp. , the global authority on nicotinamide adenine dinucleotide research with a focus on healthy aging, announced toda
Read at businesswire.com
Chromadex Corp Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Chromadex Corp can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Chromadex Corp Fundamental Analysis
We analyze Chromadex Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chromadex Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chromadex Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Chromadex Corp is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Chromadex Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Chromadex Corp stock to make a market-neutral strategy. Peer analysis of Chromadex Corp could also be used in its relative valuation, which is a method of valuing Chromadex Corp by comparing valuation metrics with similar companies.
Peers
Chromadex Corp Related Equities
IPSC | Century Therapeutics | 3.85 | ||||
ANTX | AN2 Therapeutics | 3.73 | ||||
XCUR | Exicure | 3.55 | ||||
ACRV | Acrivon Therapeutics, | 2.65 | ||||
MNOV | MediciNova | 1.46 | ||||
NKTX | Nkarta | 0.77 | ||||
AVTE | Aerovate Therapeutics | 0.75 | ||||
KZR | Kezar Life | 0.54 | ||||
IKNA | Ikena Oncology | 1.16 | ||||
MLYS | Mineralys Therapeutics, | 1.42 | ||||
RZLT | Rezolute | 1.44 | ||||
JANX | Janux Therapeutics | 1.68 | ||||
ADAG | Adagene | 2.20 | ||||
ELYM | Eliem Therapeutics | 2.91 | ||||
ANEB | Anebulo Pharmaceuticals | 4.11 | ||||
HCWB | HCW Biologics | 8.20 |
Complementary Tools for Chromadex Stock analysis
When running Chromadex Corp's price analysis, check to measure Chromadex Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chromadex Corp is operating at the current time. Most of Chromadex Corp's value examination focuses on studying past and present price action to predict the probability of Chromadex Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chromadex Corp's price. Additionally, you may evaluate how the addition of Chromadex Corp to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |